Location History:
- Halle/Saale, DE (2011 - 2017)
- Halle, DE (2020 - 2021)
Company Filing History:
Years Active: 2011-2021
Title: Martin Kleinschmidt: Innovator in Humanized Antibodies
Introduction
Martin Kleinschmidt is a prominent inventor based in Halle/Saale, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 8 patents to his name, his work focuses on addressing critical health issues related to amyloidosis and related disorders.
Latest Patents
Kleinschmidt's latest patents revolve around humanized antibodies that specifically bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide. These inventions aim to provide preventive and therapeutic treatments for diseases associated with the accumulation and deposition of amyloid peptides, such as Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. His innovative approach involves the use of humanized monoclonal antibodies to bind the pyroglutamated amyloid beta peptide in various bodily fluids, including plasma, brain, and cerebrospinal fluid. This binding action is intended to prevent the accumulation or reverse the deposition of Aβ N3pE within the brain and peripheral tissues, thereby alleviating the effects of amyloidosis. Additionally, his patents include diagnostic assays for the diagnosis of amyloidosis utilizing these humanized antibodies.
Career Highlights
Throughout his career, Martin Kleinschmidt has worked
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.